Squibb to Launch New Hepatitis B Drug in China
Posted on: Thursday, 27 October 2005, 09:00 CDT
Squibb to launch new hepatitis B drug in China
SHANGHAI, Oct. 26 (Xinhua) -- Global pharmaceutical and health product manufacturing giant Bristol-Myers Squibb Co. has said it will soon launch a new hepatitis B drug in China.
The company also plans to set up a factory in Shanghai to manufacture the new drug, Chief Executive Peter Dolan said during a visit to mark 20-year founding anniversary of the company's Shanghai branch.
He said the Shanghai factory will be the only facility outside the United States to produce the hepatitis B drug, a new product that has just debuted in the US market and proven effective.
Hepatitis B is one of the most infectious diseases in China. Ministry of Health figures say the country has 130 million HBV virus carriers and 30 million chronic patients. Medical spending on HBV therapy amounts to 30 billion to 50 billion yuan (3.7 million to 6.2 million US dollars) a year in China.
Bristol-Myers Squibb Co. has a history of 118 years and the company landed in Shanghai in 1985.
Source: Xinhua News Agency - CEIS
Related Articles
- China's Hepatitis C Virus Drug Market Will Grow to $150 Million By 2012
- China's Hepatitis B Virus Drug Market Will Grow to $800 Million By 2012
- Schering-Plough Hepatitis B Drug Approved in China
- Northwest Pilots Ready to Fly Detroit-Shanghai, If China Route Authority Awarded
- Bristol-Myers Drug Suppresses Hepatitis B Virus
- Drug cuts hepatitis C virus up to 97pct
- Sinovac and LG Announce China Hepatitis Vaccine Deal
- China: Hepatitis Treatment Fails to Keep Pace With Economy
- FDA Approves New Drug for Hepatitis B
- China's Largest Metropolitan Area Embraces Next Generation Services; Nortel Networks, China Netcom Join Hands in Bringing New Experience to Subscribers in Shanghai City
 |
 |
User Comments (0)
RSS Feeds